focus -WSS

focus

author：entertainment 2025-09-30 17:59:34 - browse：3218

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

explore

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

STAT Readout: Friday, Oct. 20 biotech updates

STAT Summit: Meghan O’Rourke on making chronic illness visible

STAT Summit: Meghan O’Rourke on making chronic illness visible

Results on Novartis prostate cancer therapy could expand its use

STAT Readout: Friday, Oct. 20 biotech updates

Wikipedia

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

The problems with dementia villages

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Researchers test human milk's ability to repair gut microbiome

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth, Optum discontinue NaviHealth name

Moonlake's readout produced a cash windfall. Risks remain

Scientific mystery highlights the blind spots in genomics databases

Sports medicine is finally prioritizing gender equality

How AI can help patients find reliable information about doctors

focus

STAT Summit: How researchers deal with rejection

First Opinion on colorectal cancer screening: letter and response

First Opinion on colorectal cancer screening: letter and response

Smaller biotechs seek to piggyback on weight loss drug boom

People with mental disorders often marry others with same

Drug companies' payments and gifts affect physicians' prescribing

hotspot

focus

explore

leisure time